These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

147 related items for PubMed ID: 1100306

  • 1. Relative potency of prorenoate and spironolactone in normal man.
    Ramsay L, Harrison I, Shelton J, Tidd M.
    Clin Pharmacol Ther; 1975 Oct; 18(4):391-400. PubMed ID: 1100306
    [Abstract] [Full Text] [Related]

  • 2. Antagonism of endogenous mineralocorticoids in normal subjects by prorenoate potassium and spironolactone.
    Levine D, Ramsay L, Auty R, Branch R, Tidd M.
    Eur J Clin Pharmacol; 1976 Mar 22; 09(5-6):381-6. PubMed ID: 786663
    [Abstract] [Full Text] [Related]

  • 3. The pharmacodynamics of single doses of prorenoate potasssium and spironolactone in fludrocortisone treated normal subjects.
    Ramsay LE, Shelton JR, Tidd MJ.
    Br J Clin Pharmacol; 1976 Jun 22; 3(3):475-82. PubMed ID: 788750
    [Abstract] [Full Text] [Related]

  • 4. Spironolactone and canrenoate-K: relative potency at steady state.
    Ramsay L, Asbury M, Shelton J, Harrison I.
    Clin Pharmacol Ther; 1977 May 22; 21(5):602-9. PubMed ID: 858213
    [Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6. Spironolactone and potassium canrenoate in normal man.
    Ramsay L, Shelton J, Harrison I, Tidd M, Asbury M.
    Clin Pharmacol Ther; 1976 Aug 22; 20(2):167-77. PubMed ID: 780038
    [Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9. Relative potency of prorenoate potassium and spironolactone in attenuating diuretic induced hypokalaemia.
    McInnes GT, Harrison IR, Shelton JR, Perkins RM, Clarke JM.
    Br J Clin Pharmacol; 1984 Aug 22; 18(2):169-74. PubMed ID: 6487456
    [Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11. Bioassay of aldosterone antagonists in normal human subjects: a relationship between the level of plasma uric acid before treatment and apparent drug responses.
    Ramsay LE, Hessian P, Tidd MJ.
    Br J Clin Pharmacol; 1975 Jun 22; 2(3):271-6. PubMed ID: 1234508
    [Abstract] [Full Text] [Related]

  • 12. Paradoxical potassium excretion in response to aldosterone antagonists.
    Ramsay LE, Harrison IR, Shelton JR, Tidd MJ.
    Eur J Clin Pharmacol; 1977 Jan 03; 11(2):101-5. PubMed ID: 837961
    [Abstract] [Full Text] [Related]

  • 13. Quantitative comparison of aldosterone antagonists in normal human subjects: prediction of therapeutic potency.
    McInnes GT, Harrison IR, Shelton JR, Perkins RM.
    Br J Clin Pharmacol; 1981 Nov 03; 12(5):743-7. PubMed ID: 7332740
    [Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15. Prolactin, diuretics and urinary electrolytes in normal subjects.
    Auty R, Branch RA, Cole EN, Levine D, Ramsay L.
    J Endocrinol; 1976 Aug 03; 70(2):173-81. PubMed ID: 965879
    [Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17. Bioassay of a new aldosterone antagonist and evaluation of a simple method of quantitative comparison.
    McInnes GT, Shelton JR, Asbury MJ, Harrison IR, Clarke JM, Ramsay LE, Venning GR.
    Clin Pharmacol Ther; 1981 Aug 03; 30(2):218-25. PubMed ID: 7249505
    [Abstract] [Full Text] [Related]

  • 18. Dose-response relationships for spironolactone at steady state.
    McInnes GT, Perkins RM, Shelton JR, Harrison IR.
    Clin Pharmacol Ther; 1982 Mar 03; 31(3):317-23. PubMed ID: 7060315
    [Abstract] [Full Text] [Related]

  • 19. Detection and comparative evaluation of aldosterone antagonists in glucocorticoid-treated, adrenalectomized rats.
    Casals-Stenzel J, Buse M, Losert W.
    Eur J Pharmacol; 1982 May 07; 80(1):37-45. PubMed ID: 7095004
    [Abstract] [Full Text] [Related]

  • 20. Effect of mineralocorticoid activity on transtubular potassium gradient, urinary [K]/[Na] ratio, and fractional excretion of potassium.
    Chacko M, Fordtran JS, Emmett M.
    Am J Kidney Dis; 1998 Jul 07; 32(1):47-51. PubMed ID: 9669423
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 8.